학술논문
Efficacy and Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis with a Suboptimal Response to Previous Disease-Modifying Therapies (1-Year Interim Results)
Document Type
Abstract
Author
Source
In Multiple Sclerosis and Related Disorders January 2020 37
Subject
Language
ISSN
2211-0348